Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response

Chemoresistance remains a major treatment obstacle in multiple myeloma (MM). Novel new therapies are thus in need. Transient Receptor Potential Vanilloid type 1 (TRPV1) is a calcium-permeable ion channel that ...

Source: Journal of Hematology and Oncology - November 25, 2020 Category: Hematology Authors: Katia Beider, Evgenia Rosenberg, Valeria Dimenshtein-Voevoda, Yaarit Sirovsky, Julia Vladimirsky, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Zohar Bromberg, Lola Weiss, Amnon Peled and Arnon Nagler Tags: Research Source Type: research